Solid tumors: site, stage, biology and treatment intent
Establish the diagnosis and treatment question
Solid-tumor reasoning integrates the actual tissue diagnosis, anatomical extent, biology, functional status and the purpose of treatment. An abnormal scan or circulating marker is not equivalent to a complete histological diagnosis. A small surface diameter does not by itself establish the T category in a cancer staged by invasion depth or involved structures. Clinical, pathological and post-treatment staging can differ. A complete decision also distinguishes curative local treatment, perioperative systemic therapy, metastatic disease control and symptom-directed treatment. An effective metastatic regimen is not automatically an established adjuvant regimen.
Breast and thoracic disease
Breast assessment includes hormone receptors, HER2 findings and the actual risk context. Endocrine therapy, ovarian suppression, chemotherapy and targeted treatment address different mechanisms. A genomic recurrence assay is useful only in an appropriate validated population and should not be transferred to every receptor subtype. Residual disease after a particular neoadjuvant course is a different state from an untreated small tumor. In lung cancer, histology, actionable drivers and immune-marker assessment can change the systemic choice. A high PD-L1 result does not erase a relevant oncogenic driver. Potentially curable local disease, unresectable regional disease and disseminated disease need distinct multidisciplinary plans rather than a common chemotherapy slogan.
Digestive and genitourinary cancers
Colorectal treatment considers the primary location, RAS and BRAF findings, mismatch-repair status and resectability as appropriate. A molecular result can identify resistance as well as a possible target. Gastroesophageal, pancreatic, hepatobiliary and stromal tumors have different biology and treatment pathways. A drug supported as maintenance after controlled disease should not be described as established maintenance after progression through the qualifying treatment. Liver function, portal hypertension and bleeding risk can affect hepatocellular-cancer options. In prostate, renal, urothelial and germ-cell tumors, hormone dependence, prior treatment, organ function, risk classification and the actual histology all matter. A residual germ-cell mass is evaluated with markers, location and size rather than an unconditional operation for any post-treatment image.
Gynecologic and other solid tumors
Ovarian, endometrial, cervical and vulvar disease do not share one staging or treatment algorithm. Reproductive wishes, molecular classification, nodal assessment and prior therapy contribute to planning. A marker can be useful for follow-up without proving the primary site. Melanoma, sarcoma and neuroendocrine disease require their own anatomical and biological context. Preserve the distinction between a recognized option, a trial-defined result and the preferred current plan for an individual. These foundations do not independently establish local reimbursement, medicine availability, every updated indication or practical procedural competence.